#Ash22 - Twitter Hashtag

8 months ago

Novel Associations between Clonal Hematopoiesis [CH] and Therapeutic Exposures Revealed in Patients with Solid Tumors Using Real World Evidence [Dec 10, 2022] Sonnenschein et al. @TempusLabs #ASH22 Abstract 1227 https://t.co/KWixe4xp5u #CHIP #ccus #leusm

0

4

2

1

183

Emma M. Groarke @emmamgroarke

8 months ago

#ASHThrowback to #ASH22 in New Orleans! Hanging with my NHLBI crew @bhavishap29 @fergutierrezro1 Jen Lotter & Alana Vicente, and of course our favorite blood cells at the President’s Reception! @ASH_hematology

emmamgroarke's tweet photo. #ASHThrowback to #ASH22 in New Orleans! Hanging with my NHLBI crew @bhavishap29 @fergutierrezro1 Jen Lotter & Alana Vicente, and of course our favorite blood cells at the President’s Reception! @ASH_hematology https://t.co/sginQvmlPe

0

12

0

1

624

Mike Thompson, MD, PhD, FASCO

@mtmdphd

about 1 year ago

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM) [Dec 10, 2022] Lee et al. Abst 101 #ASH22 https://t.co/uFh0vyd5mx #mmsm #CARTcell #PrecisionMedicine

0

5

1

0

382

Mike Thompson, MD, PhD, FASCO

@mtmdphd

about 1 year ago

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM) [Dec 10, 2022] @camilagdeblois et al. Abst 99 #ASH22 https://t.co/izMBdiswlP #mmsm #mmMRD

mtmdphd's tweet photo. Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM) [Dec 10, 2022] @camilagdeblois et al. Abst 99 #ASH22 https://t.co/izMBdiswlP #mmsm #mmMRD https://t.co/YKa8nTrYuP

0

6

1

428

Don'Ki'Shot @marionnetisste

about 1 year ago

J'veux pas de sa kechne'Type Avec elle je suis pas réceptif #B22 #MOVIETAPE #ASH22

0

2

1

0

114

Mike Thompson, MD, PhD, FASCO

@mtmdphd

over 1 year ago

BMT w/in 4 wks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study [Sat, Dec 10, 2022] @MeeraMohanMD Abst 387 #ASH22 https://t.co/4MtPzSBsq0 #COVID19nCancer #bmtsm #IDonc #COVID19 #AMLsm #leusm OR 49.6

mtmdphd's tweet photo. BMT w/in 4 wks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study [Sat, Dec 10, 2022] @MeeraMohanMD Abst 387 #ASH22 https://t.co/4MtPzSBsq0 #COVID19nCancer #bmtsm #IDonc #COVID19 #AMLsm #leusm OR 49.6 https://t.co/bATyTLLMdv

0

2

1

0

338

Monica Guzman

@DrMonicaGuzman

over 1 year ago

One of my favorite things about ASH is the ability to connect with colleagues around the world that become friends as we build collaborations that eventually are presented! #ASH24 (pictures at the end was taken at #ASH22) @WCMLeukemia @RobozGailJ @Nuria_Mencia @JKanerMD

DrMonicaGuzman's tweet photo. One of my favorite things about ASH is the ability to connect with colleagues around the world that become friends as we build collaborations that eventually are presented! #ASH24 (pictures at the end was taken at #ASH22) @WCMLeukemia @RobozGailJ @Nuria_Mencia @JKanerMD https://t.co/RqAz5RJNuP

0

8

1

0

521

Bruno Paiva @BrunoPaiva_UNAV

over 1 year ago

#ASH24 #ASH23 #ASH22 every year the @iStopMM is making great contributions! This year, in MGUS patients with low/transient M-component, absence of clonal plasma cells in the bone marrow is associated with almost no risk of transformation This is what we aim with @NO_MORE_MGUS

BrunoPaiva_UNAV's tweet photo. #ASH24 #ASH23 #ASH22 every year the @iStopMM is making great contributions!

This year, in MGUS patients with low/transient M-component, absence of clonal plasma cells in the bone marrow is associated with almost no risk of transformation

This is what we aim with @NO_MORE_MGUS https://t.co/gOfmKHLJTp

1

23

6

2

2K

Taishi Yonezawa

@TaishiYonezawa

over 1 year ago

Good morning! We're survivors! We've got more survivors in #ASH24 since #ASH22! Let's thank everyone who contributed to science and medicine @ASH_hematology! @TheDoctorIsVin @CarmeloGurnari @HBlackwell17 If you have similar circumstances, please join us! at #ASH25

TaishiYonezawa's tweet photo. Good morning! We're survivors!
We've got more survivors in #ASH24 since #ASH22! Let's thank everyone who contributed to science and medicine @ASH_hematology! @TheDoctorIsVin @CarmeloGurnari @HBlackwell17 If you have similar circumstances, please join us! at #ASH25 https://t.co/qSvhAyHszf

0

15

2

1

2K

Mike Thompson, MD, PhD, FASCO

@mtmdphd

almost 2 years ago

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM) [Dec 10, 2022] Lee et al. Abst 101 #ASH22 https://t.co/uFh0vydDc5… #mmsm #CARTcell #PrecisionMedicine HT @SusanBal9

0

3

0

330

OncoDaily

@oncodaily

about 2 years ago

The best abstract at ASH 2022 is now fully published - @ManniMD1 @iStopMM @ingigerdursv @sykristinsson @SaemundurMD @DrOlaLandgren https://t.co/UT1NL7kmzx #ASH22 #Cancer #OncoDaily #Oncology #Rheumatology

0

11

1

0

228

Mike Thompson, MD, PhD, FASCO

@mtmdphd

about 2 years ago

Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Pts w/ Relapsed / Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens [Dec 12, 2022] @End_myeloma et al. Abst 4530 #ASH22 https://t.co/kx4zzLL9tl #mmsm #ClinicalTrials #caxtx

$mtmdphd's tweet photo. Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Pts w/ Relapsed / Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens [Dec 12, 2022] @End_myeloma et al. Abst 4530 #ASH22 https://t.co/kx4zzLL9tl #mmsm #ClinicalTrials #caxtx https://t.co/3V83U4iUlc$

0

8

3

0

913

Mike Thompson, MD, PhD, FASCO

@mtmdphd

about 2 years ago

Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM) [Dec 10, 2022] Lee et al. Abst 101 #ASH22 https://t.co/uFh0vyd5mx #mmsm #CARTcell #PrecisionMedicine

0

2

1

0

411

Rahul Banerjee, MD, FACP

@RahulBanerjeeMD

about 2 years ago

@tina_hemepharm @majorajay @ASH_hematology But many times I’ve tried to scour the Internet (including Twitter photos) for a fascinating poster from #ASH22 #ASH23 etc and been unable to find it… So having the key figure readily available in the abstract itself has been tremendously helpful! Unfortunately no longer :(

0

3

1

0

451

Jacob Plieth

@JacobPlieth

over 2 years ago

$HARP Pretty decent BCMA data at #ASH22 (among a hugely competitive field) https://t.co/Fkx3ANeGh9 Pretty decent DLL3 data at #ESMO23 (overshadowed by tarlatamab) https://t.co/bkxwSVNqaX

Madeleine Armstrong @ByMadeleineA

almost 3 years ago

Efficacy data with $HARP DLL3-targeting T-cell engager in SCLC and NEPC. This is with the 1mg priming dose - the company had to drop down to this after tox with the 2mg priming dose #ESMO23

ByMadeleineA's tweet photo. Efficacy data with $HARP DLL3-targeting T-cell engager in SCLC and NEPC. This is with the 1mg priming dose - the company had to drop down to this after tox with the 2mg priming dose #ESMO23 https://t.co/32gvkOIBHZ

2

20

5

8

15K

0

3

1

4K

Andrew Yee, MD

@andrew02114

over 2 years ago

Cilta-cel data after prior BCMA therapy presented by @CohenAd_MMdoc #ASH22 https://t.co/goN239hZES and published https://t.co/7K25gWmg7K

0

4

0

441

Rahul Banerjee, MD, FACP

@RahulBanerjeeMD

over 2 years ago

@HiraSMian @Taxkourel @NorthTxMSG @statnews @ManniMD1 @HadidiSamer @Eddie_Cliff @szusmani @VincentRK Agreed on all fronts - thank you both! (And congrats, Tax!) I think the #ASH22 #MMsm abstract is this one by @SantiagoThibaud right? 15/90 CAR-T recipients were eventually Dx'ed with MDS, esp. in those with long-term cytopenias. More research to come! https://t.co/hQ7ZR7nzg4

1

3

1

1K

Samer Al Hadidi, MD,MS,FACP

@HadidiSamer

over 2 years ago

@AaronGoodman33 You are still at #ASH22 , we are #ASH23 Dara-Rd is a great option for transplant ineligible patients unless we have better (efficacy and safety) we should stick with what we know works well

0

1

0

1K

Top Tweets for #Ash22

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users